Portal de Periódicos da CAPES

Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review

2020; Karger Publishers; Volume: 98; Issue: 4 Linguagem: Inglês

10.1159/000505427

1423-0232

Violante Di Donato, Innocenza Palaia, Debora D’Aniello, Lucia Musacchio, Giusi Santangelo, Federica Mauro, Anna Di Pinto, Angela Musella, Margherita Fischetti, Federica Tomao, Giorgia Perniola, Pierluigi Benedetti Panici,

Ovarian cancer diagnosis and treatment

Purpose: The objective of this study was to evaluate the impact of hormone replacement therapy (HRT) on the prognosis in endometrial cancer (EC) survivors. Methods: The research was conducted using the following electronic databases: MEDLINE (PubMed), Web of Science, ClinicalTrial.gov, and Cochrane Library. We performed a review of studies published from January 1986 to January 2019. We selected studies that included EC patients submitted to surgery with curative intent and postoperative use of HRT. Result: Seven of 1,332 abstracts considered were eligible: 4 retrospective series, 1 prospective study, 1 randomized controlled trial, and 1 population study. Globally in the observed studies there was not a significant increase in the recurrence rate, measured by the relative risk, in the EC survivors using HRT compared with the controls in tumour stages I and II. The bias was that HRT was prescribed only to low-risk patients, who were young and had a low stage of disease. Conclusion: This systematic review shows that HRT use had no negative effect on prognosis in EC survivors in tumour stages I and II.